📊 FBIOP Key Takeaways
Is Fortress Biotech, Inc. (FBIOP) a Good Investment?
Fortress Biotech exhibits severe operational losses (-138.7% operating margin) with negative free cash flow of -$53.2M, indicating the company is burning cash despite modest revenue growth of 4.6%. The disconnect between negative operating income and positive net income raises concerns about sustainability, and the company's cash runway will be critical to monitor given ongoing operational cash burn.
Fortress Biotech shows weak core fundamentals: revenue growth is modest, gross margin is very low, and operating losses are extremely large relative to sales. The positive net income and ROE appear low quality given deeply negative operating cash flow and negative operating margin, suggesting earnings are being supported by non-core or non-cash items rather than durable business performance. Liquidity is currently adequate, but continued cash burn and weak interest coverage materially pressure the fundamental outlook.
Why Buy Fortress Biotech, Inc. Stock? FBIOP Key Strengths
- Strong liquidity position with $86.2M in cash and 2.19x current ratio providing near-term operational runway
- Positive net margin of 22.8% and growing net income (+17.7% YoY) suggest potential profitability improvement trajectory
- Moderate leverage at 0.86x debt-to-equity ratio with reasonable balance sheet structure
- Solid liquidity with $86.22M in cash and a 2.19x current ratio
- Revenue is still growing modestly year over year
- Balance sheet leverage is not yet extreme with debt-to-equity at 0.86x
FBIOP Stock Risks: Fortress Biotech, Inc. Investment Risks
- Severe operating losses of -$65.4M with operating margin of -138.7% indicating core business is unprofitable at scale
- Significant negative free cash flow of -$53.2M (-112.8% FCF margin) means the company is burning through cash reserves at an unsustainable rate
- Operating cash flow negative at -$53.2M while net income is positive suggests earnings quality concerns and potential non-cash gains masking operational deterioration
- Cash burn rate of approximately $53M annually means current $86.2M cash balance provides less than 2 years of runway without achieving positive operations
- Core operations are highly unprofitable with a -138.7% operating margin
- Cash generation is very weak with -$53.23M in operating cash flow and free cash flow
- Interest coverage is negative, indicating debt servicing depends on external funding or non-operating income
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Cash runway and burn rate relative to milestone achievements
- Operating margin progression and evidence of cost control initiatives
- Revenue growth acceleration needed to reach profitability at current cost structure
- Operating cash flow burn relative to cash balance
- Gross margin and operating margin improvement
Fortress Biotech, Inc. (FBIOP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.19x current ratio provides a solid financial cushion.
FBIOP Profit Margin, ROE & Profitability Analysis
FBIOP vs Healthcare Sector: How Fortress Biotech, Inc. Compares
How Fortress Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Fortress Biotech, Inc. Stock Overvalued? FBIOP Valuation Analysis 2026
Based on fundamental analysis, Fortress Biotech, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Fortress Biotech, Inc. Balance Sheet: FBIOP Debt, Cash & Liquidity
FBIOP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Fortress Biotech, Inc.'s revenue has remained relatively flat over the 5-year period, with a 3% decline. The most recent EPS of $-2.69 indicates the company is currently unprofitable.
FBIOP Revenue Growth, EPS Growth & YoY Performance
FBIOP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $14.6M | $5.9M | $0.11 |
| Q2 2025 | $14.9M | $4.9M | $0.02 |
| Q1 2025 | $13.0M | -$10.6M | $-0.48 |
| Q3 2024 | $14.6M | -$5.0M | $-0.76 |
| Q2 2024 | $14.9M | -$10.9M | $-0.73 |
| Q1 2024 | $12.2M | -$15.4M | N/A |
| Q3 2023 | $15.3M | -$5.0M | $-0.94 |
| Q2 2023 | $17.0M | -$21.4M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Fortress Biotech, Inc. Dividends, Buybacks & Capital Allocation
FBIOP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Fortress Biotech, Inc. (CIK: 0001429260)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FBIOP
What is the AI rating for FBIOP?
Fortress Biotech, Inc. (FBIOP) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FBIOP's key strengths?
Claude: Strong liquidity position with $86.2M in cash and 2.19x current ratio providing near-term operational runway. Positive net margin of 22.8% and growing net income (+17.7% YoY) suggest potential profitability improvement trajectory. ChatGPT: Solid liquidity with $86.22M in cash and a 2.19x current ratio. Revenue is still growing modestly year over year.
What are the risks of investing in FBIOP?
Claude: Severe operating losses of -$65.4M with operating margin of -138.7% indicating core business is unprofitable at scale. Significant negative free cash flow of -$53.2M (-112.8% FCF margin) means the company is burning through cash reserves at an unsustainable rate. ChatGPT: Core operations are highly unprofitable with a -138.7% operating margin. Cash generation is very weak with -$53.23M in operating cash flow and free cash flow.
What is FBIOP's revenue and growth?
Fortress Biotech, Inc. reported revenue of $47.2M.
Does FBIOP pay dividends?
Fortress Biotech, Inc. pays dividends, with $0.5M distributed to shareholders in the trailing twelve months.
Where can I find FBIOP SEC filings?
Official SEC filings for Fortress Biotech, Inc. (CIK: 0001429260) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FBIOP's EPS?
Fortress Biotech, Inc. has a diluted EPS of $0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FBIOP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Fortress Biotech, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FBIOP stock overvalued or undervalued?
Valuation metrics for FBIOP: ROE of 19.2% (sector avg: 15%), net margin of 22.8% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy FBIOP stock in 2026?
Our dual AI analysis gives Fortress Biotech, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is FBIOP's free cash flow?
Fortress Biotech, Inc.'s operating cash flow is $-53.2M, with capital expenditures of $0.0. FCF margin is -112.8%.
How does FBIOP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 22.8% (avg: 12%), ROE 19.2% (avg: 15%), current ratio 2.19 (avg: 2).